Frequently bought together

Brand : PEPTAZOLE

PEPTAZOL 30/MG EC CAP 14/CAP

45.95

Sku : I-005074
Key features
Peptazole 30mg Capsule 14 Capsules (PEPTAZOLE) is an enteric-coated capsule containing the active ingredient lansoprazole 30 mg. It irreversibly inhibits the H+/K+-ATPase (proton pump) in gastric parietal cells, blocking the final step of acid secretion and thereby reducing gastric acid production. It is indicated for duodenal and gastric ulcers, NSAID-associated gastric and duodenal ulcers, gastroesophageal reflux disease (GERD) and erosive esophagitis, for Helicobacter pylori eradication as part of combination therapy, and for Zollinger-Ellison syndrome. Available by prescription as enteric-coated capsules in a pack of 14 capsules.
- Brand: PEPTAZOLE
- Active Ingredient: LANSOPRAZOLE 30mg
- Strength: 30mg
- Dosage Form: Capsule
- Pack Size: 14 Capsules
- Route: Oral use
- Prescription Status: Prescription
- Therapeutic Class: Gastrointestinal
- Pharmacological Group: Proton Pump Inhibitors
- Drug Class: Proton Pump Inhibitor (PPI)
- Manufacturer: SPIMACO
- Country of Origin: Saudi Arabia
- SFDA Registration No.: 1005222005
- Shelf Life: 36 months
- Storage: store below 30°c
- Gi Condition: Acid Reflux/GERD, Ulcer

Frequently bought together

Description

Specification

Indications

Approved Uses

Duodenal ulcer, gastric ulcer, NSAID-associated gastric and duodenal ulcers, gastroesophageal reflux disease (GERD), erosive esophagitis, Helicobacter pylori eradication (in combination therapy), Zollinger-Ellison syndrome

Dosage & Administration

Children's Dosage

Children 1-11 years (≤30kg): 15mg once daily; (>30kg): 30mg once daily. Children 12-17 years: 15-30mg once daily. Not approved under 1 year of age

Side Effects

Common Side Effects

Headache, diarrhea, nausea, abdominal pain, constipation, flatulence, dizziness

Side Effect Frequency

Common (1-10%): headache, diarrhea, nausea, abdominal pain, constipation, flatulence, dizziness. Uncommon (<1%): hypomagnesemia (with prolonged use), acute interstitial nephritis, Stevens-Johnson syndrome, toxic epidermal necrolysis, Clostridium difficile-associated diarrhea

Safety & Warnings

Age Restriction

Not approved under 1 year of age

Driving Warning

Safe

Drug Interactions

Atazanavir (reduced absorption - avoid), rilpivirine (reduced efficacy - contraindicated), clopidogrel (reduced antiplatelet effect via CYP2C19 inhibition), methotrexate (increased methotrexate levels), warfarin (increased INR - monitor), digoxin (increased digoxin levels), ketoconazole/itraconazole (reduced antifungal absorption), sucralfate (delayed lansoprazole absorption - take lansoprazole 30 minutes before sucralfate), tacrolimus (increased tacrolimus levels)

Food Interaction

Take 30-60 minutes before meals (preferably before breakfast) for optimal efficacy

Special Populations

Breastfeeding

Caution

Children

Children 1-11 years (≤30kg): 15mg once daily; (>30kg): 30mg once daily. Children 12-17 years: 15-30mg once daily. Not approved under 1 year of age

Elderly

No specific dosing adjustment for elderly patients; monitor for hypomagnesemia and vitamin B12 deficiency with long-term use

Kidney Impairment

No adjustment needed

Liver Impairment

Mild-to-moderate impairment: no adjustment needed. Severe impairment (Child-Pugh C): maximum dose 15mg once daily

Storage & Patient Advice

Missed Dose

Take as soon as remembered. If it is almost time for the next dose, skip the missed dose and resume the regular schedule. Do not double the dose

Overdose

Symptoms: nausea, vomiting, dizziness, abdominal pain, diarrhea, flushing, headache, tachycardia. No specific antidote. Treatment: symptomatic and supportive care. Lansoprazole is not significantly removed by hemodialysis. Seek immediate medical attention

Pharmacology

Mechanism of Action

Irreversibly inhibits the H+/K+-ATPase enzyme (proton pump) in gastric parietal cells, blocking the final step of acid secretion and reducing gastric acid production

Duration of Effect

Over 24 hours

Half-Life

1-2 hours

Metabolism

Extensive hepatic metabolism via CYP2C19 (primary) and CYP3A4

Product Information

Available Dosage Forms

Enteric-coated capsule, orally disintegrating tablet, oral suspension

Generic Availability

Yes

Gi Condition

Acid Reflux/GERD, Ulcer

Legal Disclaimer - Al Mujtama Pharmacy

The product information provided is derived from verified pharmaceutical references and is intended for general health education only. It is not a substitute for professional medical advice, diagnosis, or treatment.

Al Mujtama Pharmacy assumes no legal or medical liability for:

Any therapeutic decision made based on the information displayed without consulting a licensed physician or pharmacist
Any discrepancy between the information provided and the product's package insert or SFDA guidelines
Any misuse of medication resulting from personal interpretation of the content displayed

Important notice: Drug formulations and instructions may vary between production batches. Always rely on the leaflet included inside the product packaging you have, and consult your pharmacist or physician before starting, adjusting, or discontinuing any medication.

By using this content, you acknowledge that you have read this disclaimer and agree that Al Mujtama Pharmacy bears no liability arising from reliance on this information as a substitute for direct medical consultation.

Your health is a trust - always consult your doctor first.